Related Experiment Video
Updated: Apr 1, 2026
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
New all oral therapy for chronic hepatitis C virus (HCV): a novel long-term cost comparison
Jennifer M Poonsapaya1, Michael Einodshofer2, Heather S Kirkham1
1Walgreen Co., 1415 Lake Cook Road, MS #L411, Deerfield, IL 60015 USA.
Insights
All-oral therapy for hepatitis C virus (HCV) is more cost-effective than standard interferon-based care. This research helps payers assess HCV disease burden and treatment impact for their members.
Area of Science:
- Hepatology
- Health Economics
- Pharmacoeconomics
Background:
- Hepatitis C virus (HCV) prevalence in the US exceeds that of HIV, with 3.3 million chronically infected individuals.
- Increasing HCV diagnoses are anticipated due to an aging population and age-based screening.
- The availability of effective, all-oral antiviral therapies is expected to increase treatment utilization.
Purpose of the Study:
- To assess the disease burden and treatment impact of HCV for healthcare payors.
- To compare the economic outcomes of different HCV treatment strategies.
Main Methods:
- Developed three integrated economic models to estimate HCV disease and cost burden.
- Model 1: Estimated HCV antibody prevalence based on payer demographics.
- Model 2: Predicted future treatment and medical costs for uncured chronic HCV patients.
- Model 3: Contrasted costs of interferon-based standard of care (SOC), all-oral therapy, and natural disease progression over 14 years, considering HCV genotypes.
Main Results:
- In a US-representative payer population of 100,000, HCV seroprevalence was estimated at 1.26%.
- All-oral therapy demonstrated the lowest combined pharmacy and medical costs for uncured chronic HCV patients.
- All-oral therapy offered annual cost savings of approximately $3000 per patient compared to SOC over 14 years.
Conclusions:
- All-oral therapeutic regimens were found to be less costly than standard of care (SOC) in most modeled scenarios.
- Cost-effectiveness of all-oral therapy was maintained even in sensitivity analyses, supporting its value in HCV management.
Background:
In the US, the prevalence of hepatitis C virus (HCV) has surpassed the prevalence of human immunodeficiency virus (HIV), with about 3.3 million people chronically infected with the disease. Given the aging of the Baby Boomer generation and the subsequent implementation of age-based screening recommendations, HCV diagnoses are expected to increase. Utilization of anti-viral pharmacotherapy is also expected to increase as more effective and tolerable all-oral therapies for HCV become available in the United States. This research allows payors to assess the disease burden and treatment impact of HCV in their member group.
Methods:
A set of three integrated economic models was developed to estimate the disease and cost burden of HCV based on existing literature, wholesale acquisition costs, industry standards, and actuarial judgment. Model 1 estimates the HCV antibody prevalence of HCV in a payer's member group based on population size and the age, sex, and region distribution of the members. Model 2 predicts the number of uncured chronic HCV members who represent the future treatment and medical cost burden for the payer over the next 14 years. Model 3 contrasts the pharmacy, medical, and overall costs for treatment and medical care over 14 years for three therapeutic scenarios: interferon-based standard of care (SOC), all oral therapy, and natural course of disease progression, while accounting for the frequency of HCV genotype within the member population.
Results:
In a payer population of 100,000 members with an age, sex, and region distribution matching the United States, the seroprevalence of HCV was estimated to be 1.26 %. Combined pharmacy and medical costs for uncured chronic HCV positive members was least expensive for all oral therapy. The per patient with HCV cost savings for all oral therapy compared to SOC were about $3000 per year over 14 years. In a sensitivity analysis, the 12-week all oral therapy for genotype 1 provided overall cost savings vs. a 24-week interferon-based SOC regimen until all oral therapy costs exceeded $99,000.
Conclusions:
In most modeled scenarios, the all-oral therapeutic scenario was less costly than SOC, even in sensitivity analyses.
Related Concept Videos
01:25Hepatitis
01:10Retrovirus Life Cycles
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:28Drug Therapy
Antianxiety Medications